PDSB NASDAQ
PDS Biotechnology Corporation
1W: -6.1%
1M: +253.1%
3M: -11.5%
YTD: -10.2%
1Y: -26.6%
3Y: -85.3%
5Y: -95.5%
$0.75
+0.04 (+6.00%)
Weekly Expected Move ±48.3%
$0
$0
$1
$1
$1
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
6 relationships6
As Filer
counterparties named
0
As Counterparty
mentioned by others
3
Rel. Types
2022-08-24
Earliest Filing
2025-02-28
Latest Filing
partner: 4
licensee: 1
investor: 1
Counterparties (Filed by PDSB)
6 relationshipsCompanies named in PDSB's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| A.G.P./Alliance Global Partners | — | partner | Placement agent for the securities offering | 2025-02-28 | View |
| H.C. Wainwright & Co., LLC | — | partner | Mentioned in connection with an existing ATM sales agreement | 2025-02-28 | View |
| H.C. Wainwright & Co., LLC | — | partner | Sales agent for at-the-market stock offering | 2024-08-13 | View |
| Merck KGaA, Darmstadt, Germany | MRK | licensee | Granted exclusive license for NHS-IL12 fusion protein M9241 and received equity and cash payments. | 2023-01-03 | View |
| Powerscourt Investments XXV, LP | — | investor | Warrant holder in connection with the Venture Loan and Security Agreement | 2022-08-24 | View |
| BTIG, LLC | — | partner | Sales agent for the At Market Issuance Sales Agreement | 2022-08-24 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-09-22 | Other Events; Exhibits | View | |
| 2026-09-21 | Other Events; Exhibits | View | |
| 2026-09-14 | Termination of Agreement; Officer/Director Change; Regulation FD; Other Events; Exhibits | View | |
| 2026-09-08 | Material Agreement; Unregistered Equity Sales; Regulation FD; Exhibits | Agreement | View |
| 2026-09-04 | Material Agreement; Financial Obligation; Exhibits | Agreement | View |
| 2026-08-25 | Exit/Disposal Costs; Officer/Director Change | View | |
| 2026-08-19 | Officer/Director Change | View | |
| 2026-08-14 | Bylaws Amendment; Shareholder Vote; Exhibits | View | |
| 2026-08-13 | Earnings Release; Exhibits | View | |
| 2026-08-11 | Regulation FD; Exhibits | View | |
| 2026-07-31 | Delisting Notice | View | |
| 2026-06-15 | Other Events | View | |
| 2026-06-15 | Material Agreement; Termination of Agreement; Financial Obligation; Unregistered Equity Sales; Exhib | Agreement | View |
| 2026-06-02 | Other Events | View | |
| 2026-05-13 | Earnings Release; Exhibits | View | |
| 2026-05-01 | Material Agreement; Termination of Agreement; Financial Obligation; Unregistered Equity Sales | Agreement | View |
| 2026-04-24 | Other Events; Exhibits | View | |
| 2026-04-15 | Other Events; Exhibits | View | |
| 2026-03-30 | Earnings Release; Exhibits | View | |
| 2026-03-03 | Notice of Delisting or Transfer | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR